## BMRN: BioMarin Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($50.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Schroder Investment Management Group Trims Holdings in BioMarin Pharmaceutical Inc. $BMRN**
- Source: MarketBeat | 20251207T053026 | Neutral | Relevance: 99%
-  Schroder Investment Management Group reduced its stake in BioMarin Pharmaceutical Inc. by 45.1% in Q2, selling 75,799 shares and retaining 92,281 shares valued at approximately $5.07 million. Despite missing recent quarterly EPS and slightly missing revenue, BioMarin set positive FY2025 guidance. Analyst sentiment for BMRN is mixed but largely positive, with a "Moderate Buy" consensus and an average target price of $88.61, while the stock currently trades around $53.40.

**2. Jump Financial LLC Grows Stake in BioMarin Pharmaceutical Inc. $BMRN**
- Source: MarketBeat | 20251208T121514 | Neutral | Relevance: 98%
-  Jump Financial LLC significantly increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 530.3% in Q2, acquiring an additional 245,017 shares to hold a total of 291,217 shares valued at approximately $16.01 million. This increase contributes to the very high institutional ownership of 98.71% for BioMarin, which also has a consensus "Moderate Buy" rating from analysts with an average price target of $88.61, notably above its current stock price of around $53. The company, despite missing Q2 earnings estimates, has set promising FY2025 guidance.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | Leerink Partner | $60 | $82 | -27% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | Leerink Partner | down | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 11.5% (-8.1%)
- Vanguard Group Inc: 9.7% (-2.2%)
- Primecap Management : 7.9% (-3.4%)
- Dodge & Cox Inc.: 7.6% (-2.8%)
- State Street Corpora: 4.6% (-0.9%)

### Key Risks

1. Long-term trend broken: trading 8.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 10.2x attractive for 47% earnings growth. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (4.8x), low leverage (D/E 0.26). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.3B |
| Beta | 0.30 |
| 52W Range | $50.76 - $73.51 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 10.2 |
| Current P/E | 15.0 |
| YoY Growth | 47.0% |
| EPS Direction | FALLING |

### Technicals

MRS_10 stable at -2.2% (minimal 5-day change). Below STRENGTH zone by 5.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 48.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.21% (CS: 34) | Weak |
| RSI_14 | 48.2 | Neutral |
| MACD Histogram | -0.16 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 0.917x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $53.74
- **Stop Loss:** $50.90 (5.3% risk)
- **Target:** $56.58 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 105
- **Position Value:** $5,642.70
- **Portfolio %:** 5.64%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-19 (Est: $0.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.31 | $0.12 | -61.1% |
| 2025Q2 | $1.01 | $1.44 | +42.3% |
| 2025Q1 | $0.95 | $1.13 | +18.6% |
| 2024Q4 | $0.74 | $0.92 | +24.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*